Comments
Loading...
Apellis Pharmaceuticals (APLS) Forecast
NewsEarningsApellis Pharmaceuticals (APLS) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestApellis Pharmaceuticals (NASDAQ:APLS) Stock Quotes, Forecast and News Summary
Apellis Pharmaceuticals Stock (NASDAQ: APLS) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Apellis Pharmaceuticals (APLS) stock?
You can purchase shares of Apellis Pharmaceuticals (NASDAQ:APLS) through any online brokerage.
Who are Apellis Pharmaceuticals (APLS) competitors?
Other companies in Apellis Pharmaceuticals’s space includes: Immunovant (NASDAQ:IMVT), Ultragenyx Pharmaceutical (NASDAQ:RARE), MoonLake (NASDAQ:MLTX), Alkermes (NASDAQ:ALKS) and SpringWorks Therapeutics (NASDAQ:SWTX).
What is the forecast, or price target, for Apellis Pharmaceuticals (APLS) stock?
Apellis Pharmaceuticals has a consensus price target of $50.68.
What is the current price for Apellis Pharmaceuticals (APLS)?
The stock price for Apellis Pharmaceuticals (NASDAQ: APLS) is $26.745 last updated November 21, 2024 at 11:06 AM EST.
Does Apellis Pharmaceuticals (APLS) pay a dividend?
There are no upcoming dividends for Apellis Pharmaceuticals.
When is Apellis Pharmaceuticals (NASDAQ:APLS) reporting earnings?
Apellis Pharmaceuticals’s Q3 earnings are confirmed for Tuesday, November 5, 2024.
Is Apellis Pharmaceuticals (APLS) going to split?
There is no upcoming split for Apellis Pharmaceuticals.
What sector and industry does Apellis Pharmaceuticals (APLS) operate in?
Apellis Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.